Your browser doesn't support javascript.
loading
Proton pump inhibitor-responsive esophageal eosinophilia: a historical perspective on a novel and evolving entity / Esofagitis eosinofílica respondedora a los inhibidores de la bomba de protones: perspectiva histórica sobre una entidad nueva y en desarrollo
Molina-Infante, Javier; Katzka, David A; Dellon, Evan S.
Affiliation
  • Molina-Infante, Javier; Hospital San Pedro de Alcántara. Cáceres. Spain
  • Katzka, David A; Mayo Clinic. Rochester. USA
  • Dellon, Evan S; University of North Carolina School of Medicine. Center for Esophageal Diseases and Swallowing. North Carolina. USA
Rev. esp. enferm. dig ; Rev. esp. enferm. dig;107(1): 29-36, ene. 2015. tab, ilus
Article in En | IBECS | ID: ibc-132226
Responsible library: ES1.1
Localization: BNCS
ABSTRACT
Eosinophilic esophagitis (EoE) is an emerging chronic esophageal disease, first described in 1993, with a steadily increasing incidence and prevalence in western countries. Over the 80´s and early 90´s, dense esophageal eosinophilia was mostly associated gastroesophageal reflux disease (GERD). For the next 15 years, EoE and GERD were rigidly considered separate entities: Esophageal eosinophilia with pathological acid exposure on pH monitoring or response to proton pump inhibitor (PPI) therapy was GERD, whereas normal pH monitoring or absence of response to PPIs was EoE. Updated guidelines in 2011 described a novel phenotype, proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE), referring to patients who appear to have EoE clinically, but who achieve complete remission after PPI therapy. Currently, PPI-REE must be formally excluded before diagnosing EoE, since 30-40 % of patients with suspected EoE are eventually diagnosed with PPI-REE. Interestingly, PPI-REE and EoE remain undistinguishable based on clinical, endoscopic, and histological findings, pH monitoring, and measurement of tissue markers and cytokines related to eosinophilic inflammation. This review article aims to revisit the relatively novel concept of PPI-REE from a historical perspective, given the strong belief that only GERD, as an acid peptic disorder, could respond to the acid suppressing ability of PPI therapy, is becoming outdated. Evolving evidence suggests that PPI-REE is genetically and phenotypically undistinguishable from EoE and PPI therapy alone can almost completely reverse allergic inflammation. As such, PPI-REE might constitute a subphenotype of EoE and PPI therapy may be the first therapeutic step and diet/ steroids may represent step up therapy. Possibly, the term PPI-REE will be soon replaced by PPIresponsive EoE. The mechanism as to why some patients respond to PPI therapy (PPI-REE) while others do not (EoE), remains to be elucidated
Subject(s)
Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Gastroesophageal Reflux / Proton Pumps / Eosinophilic Esophagitis Type of study: Guideline / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Rev. esp. enferm. dig Year: 2015 Document type: Article
Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Gastroesophageal Reflux / Proton Pumps / Eosinophilic Esophagitis Type of study: Guideline / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Rev. esp. enferm. dig Year: 2015 Document type: Article